PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.

被引：9

作者：

Bidard, Francois Clement

Sabatier, Renaud

Berger, Frederique

Pistilli, Barbara

Dalenc, Florence

Rouge, Thibault De La Motte

Frenel, Jean-Sebastien

Dubot, Coraline

Ladoire, Sylvain

Ferrero, Jean-Marc

Stefani, Laetitia

Lortholary, Alain

Hardy-Bessard, Anne-Claire

Grenier, Julien

Everhard, Sibille

Jeannot, Emmanuelle

Proudhon, Charlotte

Lemonnier, Jerome

Delaloge, Suzette

Bachelot, Thomas Denis

机构：

[1] Inst Curie, Paris, France

[2] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France

[3] Inst Curie, Biostat Unit, INSERM U900, Paris, France

[4] Gustave Roussy, Dept Med Oncol, Villejuif, France

[5] INSERM, Inst Claudius Regaud, IUCT Oncopole, CRCT, Toulouse, France

[6] Ctr Eugene Marquis, Rennes, France

[7] Ctr Rene Gauducheau, Inst Cancerol Ouest, St Herblain, France

[8] Inst Curie, St Cloud, France

[9] Ctr Georges Francois Leclerc, Dept Med Oncol, Dijon, France

[10] Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France

[11] CH Annecy Genevois, Dept Med Oncol, Pringy, France

[12] Hop Prive Confluent, Nantes, France

[13] CARIO HPCA, Ctr Armoricain Oncol, Plerin, France

[14] Inst St Catherine, Avignon, France

[15] UCBG, Unicanc R&D, Paris, France

[16] R&D Unicanc, Paris, France

[17] Inst Gustave Roussy, Villejuif, France

[18] Ctr Leon Berard, Dept Med Oncol, Lyon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS1105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS1105

引用

页数：1